Table 4.

Univariate analysis for progression‐free survival (PFS) following osimertinib treatment

	n	mPFS, months (95% CI)	Hazard rate (95% CI)	P‐value
Age				0.24
≥75	10	11.9 (1.6–15.3)	1
<75	28	11.9 (6.1–25.9)	0.562 (0.226–1.512)
Smoking history				0.354
Never	22	11.4 (5.8–19.6)	1
Previous/current	16	15.3 (9.6–NR)	0.655 (0.247–1.585)
Performance status				0.037
2	4	7.7 (1.6–11.0)	1
0–1	34	13.9 (9.7–25.9)	0.247 (0.082–0.906)
EGFR activating mutation				0.055
L858R	15	9.6 (5.8–11.9)	1
exon 19 del	23	19.6 (9.7–NR)	0.418 (0.170–1.018)
Treatment line of osimertinib				0.297
Second or third	22	11.4 (5.7–25.9)	1
Fourth or later	16	14.9 (9.6–NR)	0.636 (0.261–1.485)
Brain metastasis				0.742
Present	16	14.9 (5.7–19.6)	1
Absent	22	11.9 (9.6–25.9)	0.867 (0.371–2.070)
Previous treatment with afatinib				0.009
No	30	11.0 (5.8–14.9)	1
Yes	8	NR (7.5–NR)	0.203 (0.032–0.702)

CI, confidence interval; NR, not reached.